收藏切换
Discussion on research ideas of post-marketing clinical re-evaluation of traditional Chinese medicine
收藏切换
Yu-huan CHEN1, Xiao LING2, Chun-xiao LI2, Pan-pan WANG1, Shu-yu LIU1, Zhi-huan MA1, Xue-lin LI2
Chinese Journal of New Drugs | 2021, 30(24) : 2262 - 2267
Less
收藏切换
Chinese Journal of New Drugs | 2021, 30(24): 2262-2267
Discussion on research ideas of post-marketing clinical re-evaluation of traditional Chinese medicine
Full
Yu-huan CHEN1, Xiao LING2, Chun-xiao LI2, Pan-pan WANG1, Shu-yu LIU1, Zhi-huan MA1, Xue-lin LI2
Affiliations
  • 1Henan University of Chinese Medicine, Zhengzhou 450046, China
  • 2Henan Province Engineering Laboratory for Clinical Evaluation Technology of Chinese Medicine, the First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou 450000, China
Published: 2021-12-30
Outline
收藏切换

The re-evaluation system of western medicines at home and abroad has been preliminarily formed. It is clear that the post-marketing re-evaluation of drugs must be based on the latest research data of the drugs, the purpose of the re-evaluation should be determined according to the needs of different subjects, and appropriate methods should be selected to carry out the re-evaluation research. Although the post-marketing re-evaluation research of traditional Chinese medicine has made some progress, there are still many problems in this field due to the differences in the theoretical systems of Chinese and Western medicine and the deficiencies of pre-marketing research. This article summarized the status of post-marketing clinical re-evaluation research of traditional Chinese medicine, analyzed the problems, and proposed key technology improvement methods for the post-marketing clinical re-evaluation research of Chinese patent medicines and Chinese herbal medicine pieces. It is hoped that a high-level comprehensive post-marketing clinical re-evaluation system for traditional Chinese medicines based on real world study would be formed based on multi-level, multi-source, multi-method research data and results, which will provide a basis for the rational use of traditional Chinese medicine and the formulation of national drug policies.

post-marketing clinical re-evaluation  /  clinical research  /  Chinese herbal medicine pieces  /  Chinese patent medicines  /  real world study  /  comprehensive evaluation system
陈玉欢, 凌霄, 李春晓, 王盼盼, 刘淑钰, 马志欢, 李学林. 中药上市后临床再评价研究思路探讨. 中国新药杂志, 2021 , 30 (24) : 2262 -2267 .
Yu-huan CHEN, Xiao LING, Chun-xiao LI, Pan-pan WANG, Shu-yu LIU, Zhi-huan MA, Xue-lin LI. Discussion on research ideas of post-marketing clinical re-evaluation of traditional Chinese medicine[J]. Chinese Journal of New Drugs, 2021 , 30 (24) : 2262 -2267 .
Year 2021 volume 30 Issue 24
38
7
Cite this Article
BibTeX
Article Info
  • Online Date:2026-10-28
  • Published:2021-12-30
Article Data
Affiliations
History
  • Accepted:2021-03-30
Funding
Affiliations
    1Henan University of Chinese Medicine, Zhengzhou 450046, China
    2Henan Province Engineering Laboratory for Clinical Evaluation Technology of Chinese Medicine, the First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou 450000, China
References
Share
https://castjournals.cast.org.cn/joweb/zgxyzz/EN/
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT